The role of VEGF in normal and neoplastic hematopoiesis - PubMed (original) (raw)

Review

The role of VEGF in normal and neoplastic hematopoiesis

Hans-Peter Gerber et al. J Mol Med (Berl). 2003 Jan.

Abstract

VEGF is a secreted growth factor that mediates its biological effects by binding to two transmembrane tyrosine kinase receptors, VEGFR-1 and VEGFR-2. The VEGF/receptor signaling system is involved in the regulation of two fundamental processes in vertebrates: the formation of blood vessels (angiogenesis) and of blood cells (hematopoiesis). Hematopoietic stem cells, capable of giving rise to all blood cell lineages, are often found in clusters with endothelial cells, the key cell type involved in the formation of blood vessels. Despite such proximity of VEGF-responsive cells, hematopoiesis occurs independently of neoangiogenesis in the adult bone marrow, suggesting that VEGF regulates the two processes by different mechanisms. In support of this hypothesis, the recently identified autocrine loop by which VEGF may control hematopoietic stem cell survival and repopulation, is fundamentally different from its paracrine effects regulating angiogenesis. Furthermore, coexpression of VEGF and its receptors, the prerequisite for autocrine loops, is frequently found in lymphomas and myelomas, suggesting that autocrine loops also play a role in hematological malignancies. Several therapeutic strategies blocking VEGF or VEGF-induced signaling are currently being investigated for the treatment of neoplastic diseases. They differ in their potential to interfere with the autocrine or paracrine effector functions of VEGF during angiogenesis, hematopoiesis, and tumor cell proliferation, properties which may ultimately determine their therapeutic potential.

PubMed Disclaimer

Similar articles

• Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
  Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S. Dias S, et al. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62. doi: 10.1073/pnas.191117498. Proc Natl Acad Sci U S A. 2001. PMID: 11553814 Free PMC article.
• VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
  Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N. Gerber HP, et al. Nature. 2002 Jun 27;417(6892):954-8. doi: 10.1038/nature00821. Nature. 2002. PMID: 12087404
• A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
  Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F. Vacca A, et al. Haematologica. 2003 Feb;88(2):176-85. Haematologica. 2003. PMID: 12604407
• The biology of VEGF and its receptors.
  Ferrara N, Gerber HP, LeCouter J. Ferrara N, et al. Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.
• New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?
  de Bont ES, Neefjes VM, Rosati S, Vellenga E, Kamps WA. de Bont ES, et al. Leuk Lymphoma. 2002 Oct;43(10):1901-9. doi: 10.1080/1042819021000015844. Leuk Lymphoma. 2002. PMID: 12481883 Review.

Cited by

• Reduced miR-16 levels are associated with VEGF upregulation in high-risk myelodysplastic syndromes.
  Xiong B, Nie Y, Yu Y, Wang S, Zuo X. Xiong B, et al. J Cancer. 2021 Jan 30;12(7):1967-1977. doi: 10.7150/jca.52455. eCollection 2021. J Cancer. 2021. PMID: 33753995 Free PMC article.
• Identification, isolation and expansion of myoendothelial cells involved in leech muscle regeneration.
  Grimaldi A, Banfi S, Gerosa L, Tettamanti G, Noonan DM, Valvassori R, de Eguileor M. Grimaldi A, et al. PLoS One. 2009 Oct 30;4(10):e7652. doi: 10.1371/journal.pone.0007652. PLoS One. 2009. PMID: 19876402 Free PMC article.
• Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.
  Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A. Holzer TR, et al. PLoS One. 2013 Nov 14;8(11):e80292. doi: 10.1371/journal.pone.0080292. eCollection 2013. PLoS One. 2013. PMID: 24244672 Free PMC article.
• Role of platelet-derived growth factors in physiology and medicine.
  Andrae J, Gallini R, Betsholtz C. Andrae J, et al. Genes Dev. 2008 May 15;22(10):1276-312. doi: 10.1101/gad.1653708. Genes Dev. 2008. PMID: 18483217 Free PMC article. Review.

References

1. 1. Cell. 1998 Mar 20;92(6):735-45 - PubMed
2. 1. Nature. 2002 Jun 27;417(6892):954-8 - PubMed
3. 1. Br J Haematol. 1998 Dec;103(4):969-79 - PubMed
4. 1. J Biol Chem. 2001 Feb 2;276(5):3222-30 - PubMed
5. 1. Nature. 1995 Jul 6;376(6535):66-70 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database